<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175394</url>
  </required_header>
  <id_info>
    <org_study_id>1218.44</org_study_id>
    <nct_id>NCT02175394</nct_id>
  </id_info>
  <brief_title>Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects</brief_title>
  <official_title>An Open, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1356 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective was to investigate the effect of multiple oral doses of 5 mg BI 1356 on the&#xD;
      steady-state pharmacokinetics of ethinylestradiol (EE) and levonorgestrel (LNG), the&#xD;
      components of Microgynon®&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of ethinylestradiol and levonogestrel (Microgynon®) in plasma over the dosing interval at steady-state (AUCτ,ss)</measure>
    <time_frame>On day 14 and on day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of ethinylestradiol and levonogestrel (Microgynon®) in plasma at steady state (Cmax,ss)</measure>
    <time_frame>On day 14 and on day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from last dosing to the maximum measured concentration of EE and LNG in plasma at steady state (tmax,ss)</measure>
    <time_frame>Up to day 22 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of EE and LNG in plasma following extravascular administration at steady state (CL/F,ss)</measure>
    <time_frame>Up to day 22 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of EE and LNG during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)</measure>
    <time_frame>Up to day 22 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of EE and LNG in plasma at steady state (t1/2,ss)</measure>
    <time_frame>Up to day 22 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant of EE and LNG in plasma at steady state (λz,ss)</measure>
    <time_frame>Up to day 22 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of EE and LNG in the body at steady state after oral administration (MRTpo,ss)</measure>
    <time_frame>Up to day 22 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose plasma concentrations of EE and LNG for attainment of steady state</measure>
    <time_frame>Up to day 21 after start of Microgynon® treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose plasma concentration of BI 1356 for attainment of steady state</measure>
    <time_frame>Day 15 up to 7 days after start of BI 1356 treatment (day 21)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of BI 1356</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in vital signs (BP, HR)</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinical relevant changes in laboratory evaluation (haematology, clinical chemistry and urinalysis)</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in ECG recordings</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global tolerability by the investigator, a 4-point scale</measure>
    <time_frame>Up to day 14 after last administration of study drug on day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Microgynon®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microgynon® once daily during period 1 (day 1 to day 14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microgynon® and BI 1356</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon®</intervention_name>
    <arm_group_label>Microgynon®</arm_group_label>
    <arm_group_label>Microgynon® and BI 1356</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <arm_group_label>Microgynon® and BI 1356</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy premenopausal female subjects as determined by the results of screening based&#xD;
             upon a complete medical history, including the physical examination, vital signs&#xD;
             (blood pressure (BP), heart rate (HR)), 12-lead electrocardiogram (ECG), clinical&#xD;
             laboratory tests&#xD;
&#xD;
          -  Age 18 - 40 years&#xD;
&#xD;
          -  BMI 18.5 - 27 kg/m2 (Body Mass Index)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice (GCP) and the local legislation&#xD;
&#xD;
          -  Gynaecological examination without relevant findings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination deviating from normal and of clinical&#xD;
             relevance. Systolic blood pressure greater than 140 mm Hg or diastolic blood pressure&#xD;
             greater than 90 mm Hg&#xD;
&#xD;
          -  Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (greater than 24 hours) within at least one&#xD;
             month or less than 10 half-lives of the respective drug prior to day 1 or during the&#xD;
             trial&#xD;
&#xD;
          -  Use of antibiotics and drugs known to inhibit or induce cytochrome P450 enzymes,&#xD;
             especially CYP3A4, within one month prior to study day 1 or during the trial (CYP3A4&#xD;
             inhibitors are for example azole antimycotics, macrolides, CYP3A inducers are for&#xD;
             example St. John's Wort or certain anticonvulsants)&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within two months prior to&#xD;
             day 1 or during the trial&#xD;
&#xD;
          -  Regular smokers of more than two cigarettes daily&#xD;
&#xD;
          -  Drug or alcohol abuse (more than 20 g alcohol/day)&#xD;
&#xD;
          -  Blood donation (more than 100 mL within four weeks prior to day 1)&#xD;
&#xD;
          -  Excessive physical activities within 48 hours prior to day 1)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
          -  Positive pregnancy test, pregnancy or planning to become pregnant within 2 months of&#xD;
             study completion, or lactation&#xD;
&#xD;
          -  No use of an additional contraceptive method until 6 weeks after last study drug&#xD;
             administration, i.e. barrier method, sexual abstinence, non-hormone-containing&#xD;
             intrauterine device (IUD), surgical sterilisation (incl. hysterectomy) or vasectomized&#xD;
             partner&#xD;
&#xD;
          -  Use of oral contraceptive-containing intrauterine device, depot injection or&#xD;
             contraceptive implants&#xD;
&#xD;
          -  Existing or a history of confirmed venous thromboembolism (VTE), family history of&#xD;
             idiopathic VTE and other known risk factors for VTE. Existing or previous arterial&#xD;
             thrombotic or embolic processes, conditions which predispose to them e.g. disorders of&#xD;
             the clotting processes, valvular heart disease and atrial fibrillation&#xD;
&#xD;
          -  Relevant varicosis&#xD;
&#xD;
          -  History of migraine&#xD;
&#xD;
          -  History of liver disease, i.e. disturbances of liver function, jaundice or persistent&#xD;
             itching during a previous pregnancy, Dubin-Johnson syndrome, Rotor syndrome, previous&#xD;
             or existing liver tumours&#xD;
&#xD;
          -  Clinically relevant cycle anomalies and dysmenorrhoea within the last 12 months&#xD;
&#xD;
          -  Usual menstrual cycle duration outside of a 26-32 days range&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.44_U09-1393-01.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

